Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1

被引:163
作者
Biancotto, Angelique
Grivel, Jean-Charles
Iglehart, Sarah J.
Vanpouille, Christophe
Lisco, Andrea
Sieg, Scott F.
Debernardo, Robert
Garate, Kristen
Rodriguez, Benigno
Margolis, Leonid B.
Lederman, Michael M.
机构
[1] NICHHD, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA
[2] Case Western Reserve Univ, Univ Case Med Ctr, Ctr AIDS Res, Cleveland, OH 44106 USA
关键词
D O I
10.1182/blood-2006-11-055764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is growing recognition that HIV-1 infection leads to an activation of the immune system that includes perturbations of cytokine expression, redistribution of lymphocyte subpopulations, cell dysfunction, and cell death. Here, we explored the relationships between HIV-1 infection and immune activation in chronically HIV-1-infected human lymph nodes. In addition to CD4 T-cell depletion, we found increased effector T-cell frequencies associated with profound up-regulation of an activation marker CD38 in naive, central memory, and effector CD4(+) and CD8(+) T cells. Likewise, Fas death receptor (CD95) was more frequently detectable on T cells from HIV-1 nodes. Dendritic cell (DC) depletion was dramatic, with plasmacytoid DCs (PDCs) 40-fold and myeloid DCs (MDCs) 20-fold less frequent in HIV+ nodes than in control nodes. Cytokine dysregulation was evident, with IL-2 and IL-15 as much as 2 or 3 logs greater in infected nodes than in control nodes. Thus, activated effector cells are inappropriately attracted and/or retained in lymphoid tissue in chronic HIV-1 infection. High-level cytokine expression in turn activates and retains more cells at these sites, leading to lymphadenopathy and massive bystander activation that characterizes HIV-1 infection. Strategies targeting these activation pathways may lead to new therapies.
引用
收藏
页码:4272 / 4279
页数:8
相关论文
共 56 条
  • [1] HIV - Setting death in motion
    Ameisen, JC
    [J]. NATURE, 1998, 395 (6698) : 117 - +
  • [2] Early reduction of immune activation in lymphoid tissue following highly active HIV therapy
    Andersson, J
    Fehniger, TE
    Patterson, BK
    Pottage, J
    Agnoli, M
    Jones, P
    Behbahani, H
    Landay, A
    [J]. AIDS, 1998, 12 (11) : F123 - F129
  • [3] Mechanisms of HIV-associated lymphocyte apoptosis
    Badley, AD
    Pilon, AA
    Landay, A
    Lynch, DH
    [J]. BLOOD, 2000, 96 (09) : 2951 - 2964
  • [4] Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy
    Benito, DM
    López, M
    Lozano, S
    Ballesteros, C
    Martinez, P
    González-Lahoz, J
    Soriano, V
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (04) : 373 - 381
  • [5] BENITO JM, 1997, J ACQ IMMUN DEF SYND, V4, P128
  • [6] Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses:: Relationship to viral load in untreated HIV infection
    Betts, MR
    Ambrozak, DR
    Douek, DC
    Bonhoeffer, S
    Brenchley, JM
    Casazza, JP
    Koup, RA
    Picker, LJ
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (24) : 11983 - 11991
  • [7] HIV disease: fallout from a mucosal catastrophe?
    Brenchley, JM
    Price, DA
    Douek, DC
    [J]. NATURE IMMUNOLOGY, 2006, 7 (03) : 235 - 239
  • [8] Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users
    Carbone, J
    Gil, J
    Benito, JM
    Navarro, J
    Muñóz-Fernández, A
    Bartolomé, J
    Zabay, JM
    López, F
    Fernández-Cruz, E
    [J]. AIDS, 2000, 14 (18) : 2823 - 2829
  • [9] Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin
    Clerici, M
    Sarin, A
    Berzofsky, JA
    Landay, AL
    Kessler, HA
    Hashemi, F
    Hendrix, CW
    Blatt, SP
    Rusnak, J
    Dolan, MJ
    Coffman, RL
    Henkart, PA
    Shearer, GM
    [J]. AIDS, 1996, 10 (06) : 603 - 611
  • [10] Deaglio S, 2000, CHEM IMMUNOL, V75, P99